CADL vs REPL
CADL: Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic cell death within solid tumors. REPL: Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in combination therapy for melanoma patients who have failed checkpoint inhibitors.
Side-by-side fundamentals
| Metric | CADL | REPL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.09 | $10.75 | |
| Market cap as of 2026-07-23 | $739M | $918M | |
| PEG as of 2026-07-23 | n/a | -0.34 | |
| Net margin as of 2026-07-23 | -15156.5% | n/a | |
| Operating margin as of 2026-07-23 | -28000.8% | n/a | |
| ROE as of 2026-07-23 | -60.4% | -128.6% | CADL higher |
| ROA as of 2026-07-23 | -41.3% | -82.3% | CADL higher |
| Debt / equity as of 2026-07-23 | 0.34 | 0.65 | CADL lower |
| Revenue CAGR (3y) SEC XBRL | +0.0% | n/a | |
| Beta as of 2026-07-23 | -0.46 | 0.89 | |
| 1-year return as of 2026-07-22 close | +55.6% | +283.2% | REPL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.